BUY Dr. Lal Path Labs — Chandan Taparia, 16 Sept 2026

byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))16 Sept 2026via NDTV Profit

Entry₹2,000.2Inferred

Target₹2,080

Stop loss₹1,920-4.01% risk

Exit₹1,92016 Sept 2026, 9:40 am

Stop-loss hit-4.01%

Follow Chandan Taparia for new calls(34% target hit, 179 closed calls)Get alerts Watch LALPATHLAB for new buy/sell callsGet alerts See 202 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 17 Sept, 10:31 pm IST

2 supporting0 opposing

Supports the BUY call (2)

4 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·16 Sept · today

Indian Diagnostic Giants Post Strong Q1 FY27 Growth Amid Stable Pricing

NewsGoogle News·13 Sept · 2d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Dr. Lal Path Labs Ltd. — Chandan Taparia, Motilal Oswal

AI Assessment